Table 1 from Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

Clinical trials have shown that tirzepatide significantly reduces HbA1c levels and induces substantial weight reduction, and this work reports two cases of diabetes remission after temporary tirzepatide therapy.

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.
Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.
Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...
Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c , both on a ...
Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist ...

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
FIGURE 4: Change in HbA1c values over the course of the trial and two, four, and six months after drug discontinuation - " Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series ...
Introduction To evaluate real-world hemoglobin A1c ( HbA1c ) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. Methods This retrospective analysis utilized the Healthcare Integrated ...

Impact on glycated haemoglobin and body weight changes after stopping ...
The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.






Panel of bar charts showing the mean change in A1C from baseline for pediatric and adult patients with type 2 diabetes. SURPASS-PEDS studied Mounjaro as add- on to metformin and /or basal insulin vs placebo over 30 weeks in pediatric patients 10 years of age and older with type 2 diabetes. The mean baseline A1C was 8.2%, 7.9%, 8.1%, and 8.0% for Mounjaro 5 mg, Mounjaro 10 mg, pooled Mounjaro (5 ...